MX2012003208A - Agonistas de receptores de oxitocina. - Google Patents
Agonistas de receptores de oxitocina.Info
- Publication number
- MX2012003208A MX2012003208A MX2012003208A MX2012003208A MX2012003208A MX 2012003208 A MX2012003208 A MX 2012003208A MX 2012003208 A MX2012003208 A MX 2012003208A MX 2012003208 A MX2012003208 A MX 2012003208A MX 2012003208 A MX2012003208 A MX 2012003208A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- oxytocin receptor
- maintenance
- treatment
- conditions
- Prior art date
Links
- 102000004279 Oxytocin receptors Human genes 0.000 title 1
- 108090000876 Oxytocin receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000006698 induction Effects 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 238000012423 maintenance Methods 0.000 abstract 2
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 229940122381 Oxytocin receptor agonist Drugs 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000037805 labour Diseases 0.000 abstract 1
- 230000006651 lactation Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos agonistas de receptores de oxitocina, a composiciones farmacéuticas que comprenden los mismos, al uso de estos compuestos para la manufactura de un medicamento para el tratamiento de, inter alia, dolor abdominal, síndrome de intestino irritable (lBS), autismo, disfunción eréctil, disfunción sexual femenina, inducción y mantenimiento del trabajo de parto, inducción y mantenimiento de lactación, hemorragia posparto, Trastorno de Estrés Postraumático (PTSD), dolor, ansiedad y otras condiciones, así como también a métodos para el tratamiento de estas condiciones, en donde estos compuestos se administran. Los compuestos son representados por la fórmula general (I), como se define adicionalmente en la especificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24432709P | 2009-09-21 | 2009-09-21 | |
| PCT/US2010/049714 WO2011035330A2 (en) | 2009-09-21 | 2010-09-21 | Oxytocin receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012003208A true MX2012003208A (es) | 2012-05-29 |
Family
ID=43629442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012003208A MX2012003208A (es) | 2009-09-21 | 2010-09-21 | Agonistas de receptores de oxitocina. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8748564B2 (es) |
| EP (1) | EP2491052A2 (es) |
| JP (1) | JP5750443B2 (es) |
| KR (1) | KR20120093840A (es) |
| CN (1) | CN102656183B (es) |
| AR (1) | AR078304A1 (es) |
| AU (1) | AU2010295294B2 (es) |
| BR (1) | BR112012006185A2 (es) |
| CA (1) | CA2774593C (es) |
| IL (1) | IL218649A (es) |
| IN (1) | IN2012DN02103A (es) |
| MX (1) | MX2012003208A (es) |
| NZ (1) | NZ598579A (es) |
| RU (1) | RU2539692C2 (es) |
| SA (1) | SA110310710B1 (es) |
| TW (1) | TWI463990B (es) |
| WO (1) | WO2011035330A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| BR112015014010A2 (pt) * | 2012-12-21 | 2017-07-11 | Hoffmann La Roche | peptídeos como agonistas oxitocina |
| EP3151849B1 (en) * | 2014-06-03 | 2018-10-10 | F. Hoffmann-La Roche AG | Peptides as oxytocin agonists |
| CR20160562A (es) * | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| WO2016025629A1 (en) | 2014-08-12 | 2016-02-18 | The Regents Of The University Of California | Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues |
| RS65144B1 (sr) * | 2014-09-19 | 2024-02-29 | Ferring Bv | Postupak za lečenje prader-vilijevog sindroma |
| EP3212212B1 (en) | 2014-10-31 | 2020-09-23 | Monash University | Powder formulation |
| EP3359557A1 (en) * | 2015-10-06 | 2018-08-15 | Ferring B.V. | New methods for making barusiban and its intermediates |
| CN106967155B (zh) * | 2017-03-17 | 2018-05-15 | 兰州凯博药业股份有限公司 | 一种多肽液相合成缩宫素的方法 |
| US20190135859A1 (en) | 2017-08-11 | 2019-05-09 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| AU2018340867B2 (en) * | 2017-09-28 | 2021-05-27 | Kinoxis Therapeutics Pty Ltd | Metabolite inspired selective oxytocin receptor agonists |
| US20210015807A1 (en) | 2018-03-23 | 2021-01-21 | Cytoo | Alk5 inhibitors as skeletal muscle hypertrophy inducers |
| TW202031283A (zh) | 2018-09-20 | 2020-09-01 | 馬克 Ｃ 曼寧 | 穩定卡貝縮宮素鼻內製劑 |
| TW202034899A (zh) | 2018-09-20 | 2020-10-01 | 克里斯托弗 Ｓ 布萊恩特 | 卡貝縮宮素藥品及其製備方法 |
| JP2023500763A (ja) | 2019-11-04 | 2023-01-11 | フェリング ベスローテン フェンノートシャップ | 泌乳の改善のためのメロトシンの鼻腔内投与 |
| TW202304498A (zh) | 2021-03-26 | 2023-02-01 | 法商Ｏｔ４Ｂ公司 | 吞嚥困難之治療 |
| AU2022418185A1 (en) | 2021-12-21 | 2024-05-23 | Universitaet Wien | Highly stable oxytocin derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS194980B1 (en) * | 1976-07-16 | 1979-12-31 | Joseph H Cort | Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle |
| SE430885B (sv) * | 1980-03-24 | 1983-12-19 | Ferring Ab | Oxytocin-derivat |
| CS216722B1 (en) | 1980-06-24 | 1982-11-26 | Michal Lebl | Oxytocine analogues and method of making the same |
| US4483794A (en) * | 1983-05-10 | 1984-11-20 | Ceskoslovenska Akademie Ved | Analogs of neurohypophysial hormones |
| SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| JP2004522742A (ja) * | 2000-12-08 | 2004-07-29 | ベイラー カレッジ オブ メディシン | 免疫応答の改変において使用するためのｔｒｅｍ−１スプライス改変体 |
| AU2003211011A1 (en) | 2002-02-27 | 2003-09-09 | Ferring Bv | Intermediates and methods for making heptapeptide oxytocin analogues |
| CN101379076B (zh) * | 2006-02-10 | 2012-11-07 | 辉凌公司 | 新化合物 |
-
2010
- 2010-09-08 TW TW099130296A patent/TWI463990B/zh not_active IP Right Cessation
- 2010-09-20 SA SA110310710A patent/SA110310710B1/ar unknown
- 2010-09-21 AR ARP100103440A patent/AR078304A1/es unknown
- 2010-09-21 KR KR1020127006787A patent/KR20120093840A/ko not_active Application Discontinuation
- 2010-09-21 WO PCT/US2010/049714 patent/WO2011035330A2/en active Application Filing
- 2010-09-21 IN IN2103DEN2012 patent/IN2012DN02103A/en unknown
- 2010-09-21 CA CA2774593A patent/CA2774593C/en not_active Expired - Fee Related
- 2010-09-21 US US13/496,269 patent/US8748564B2/en not_active Expired - Fee Related
- 2010-09-21 CN CN201080041788.0A patent/CN102656183B/zh not_active Expired - Fee Related
- 2010-09-21 BR BR112012006185A patent/BR112012006185A2/pt not_active IP Right Cessation
- 2010-09-21 AU AU2010295294A patent/AU2010295294B2/en not_active Ceased
- 2010-09-21 NZ NZ598579A patent/NZ598579A/en not_active IP Right Cessation
- 2010-09-21 EP EP10777131A patent/EP2491052A2/en not_active Withdrawn
- 2010-09-21 JP JP2012529981A patent/JP5750443B2/ja not_active Expired - Fee Related
- 2010-09-21 RU RU2012110349/04A patent/RU2539692C2/ru not_active IP Right Cessation
- 2010-09-21 MX MX2012003208A patent/MX2012003208A/es active IP Right Grant
-
2012
- 2012-03-15 IL IL218649A patent/IL218649A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2491052A2 (en) | 2012-08-29 |
| WO2011035330A2 (en) | 2011-03-24 |
| AU2010295294B2 (en) | 2015-12-10 |
| US8748564B2 (en) | 2014-06-10 |
| AU2010295294A8 (en) | 2012-05-31 |
| RU2012110349A (ru) | 2013-10-27 |
| TWI463990B (zh) | 2014-12-11 |
| CN102656183A (zh) | 2012-09-05 |
| TW201114434A (en) | 2011-05-01 |
| IL218649A (en) | 2016-11-30 |
| KR20120093840A (ko) | 2012-08-23 |
| IN2012DN02103A (es) | 2015-08-21 |
| JP2013505269A (ja) | 2013-02-14 |
| US20120214733A1 (en) | 2012-08-23 |
| WO2011035330A4 (en) | 2011-07-07 |
| AU2010295294A1 (en) | 2012-03-29 |
| RU2539692C2 (ru) | 2015-01-27 |
| AR078304A1 (es) | 2011-10-26 |
| CA2774593A1 (en) | 2011-03-24 |
| CN102656183B (zh) | 2016-03-30 |
| WO2011035330A3 (en) | 2011-05-19 |
| NZ598579A (en) | 2014-02-28 |
| CA2774593C (en) | 2016-12-06 |
| JP5750443B2 (ja) | 2015-07-22 |
| SA110310710B1 (ar) | 2015-01-05 |
| IL218649A0 (en) | 2012-05-31 |
| BR112012006185A2 (pt) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012003208A (es) | Agonistas de receptores de oxitocina. | |
| PH12015501289B1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
| EA031157B9 (ru) | Вводимая перорально кортикостероидная композиция | |
| MX2010004639A (es) | Formulaciones liquidas de hormona luteinizante (lh). | |
| MX342161B (es) | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. | |
| PH12015501452A1 (en) | Novel quinolone derivatives | |
| EA201270492A1 (ru) | Соединения для лечения дислипидемии и связанных с ней заболеваний | |
| MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
| TN2012000534A1 (en) | Pyrazole compounds as sigma receptor inhibitors | |
| MX2014000142A (es) | Uso de anticuerpos agonistas anti-cd83 para tratar enfermedades autoinmunes. | |
| WO2013175377A3 (en) | Compositions and methods for treatment of mucositis | |
| MX2014006433A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2. | |
| IN2014MN00697A (es) | ||
| GEP20156231B (en) | Agomelatine hydrochloride hydrate and preparation there of | |
| MX2011012669A (es) | Nuevos agonistas del receptor de glucocorticoides. | |
| MX2014002394A (es) | Inhibidores de rock suaves, novedosos. | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| IN2013DN02555A (es) | ||
| MX2013003736A (es) | Novedosos agonistas del receptor de la proteina g 119. | |
| GEP20156232B (en) | Agomelatine hydrochloride hydrate and preparation thereof | |
| EP2563785A4 (en) | Compounds as Agonists Against S1P1 Receptors | |
| IN2014KN00847A (es) | ||
| FI20106293A0 (fi) | Uudet farmaseuttiset koostumukset | |
| EA201690240A1 (ru) | Новые соединения индазола и способ их получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: FERRING B.V. |
|
| FG | Grant or registration |